Price$3.18-2.86 (-47.35%)
2026-03-042026-06-05
News · 26 weeks54-14%
2025-12-142026-06-07
Mix3290d
- SEC Filings15(47%)
- Other9(28%)
- Insider7(22%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition MechanismGrowing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today highlighted the differentiated mechanism of action of namodenoson in pancreatic cancer, including inhibition of the RAS signaling pathway, alongside encouraging clinical observations from its ongoing Phase 2a pancreatic cancer study. Recent presentations and publications emerging from the 2026 Ameri
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis MarketRamat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled "Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis" was published in the peer-reviewed journal Frontiers in Veterinary Science and is available online. The study described in the publicat
- ANALYSTCan-Fite BioPharma upgraded by D. Boral Capital with a new price targetD. Boral Capital upgraded Can-Fite BioPharma from Hold to Buy and set a new price target of $7.00
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRFollowing Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with ImmunotherapyPhase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF, TASE: CANF)), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer. The planned Phase 2b study follows encouraging findings from the Company's ongoing Phase 2a study evaluating Namodenoson in p
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 MonthsRamat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile. Key findings include: · Stable disease observed in >30% of evaluab
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- INSIDERSEC Form 3 filed by new insider Tamir Ilan3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer)
- INSIDERSEC Form 3 filed by new insider Regev Guy3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 424B3 filed by Can-Fite Biopharma Ltd424B3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form F-3 filed by Can-Fite Biopharma LtdF-3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals. The randomized, double-blind, placebo
- SECSEC Form 20-F filed by Can-Fite Biopharma Ltd20-F - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer PatientRAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study in pancreatic cancer met its primary endpoint of safety in heavily pretreated patients. The study continues to follow patients for overall survival, with data maturing over time; currently more than 30% of patients are alive at last data cut-off. Hepatocellular Carcinoma (HCC)A pat
- INSIDERSEC Form 3 filed by Can-Fite Biopharma Ltd3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer)
CANF FAQ
6 questionsWhat does Can-Fite Biopharma Ltd do?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic...Where does CANF stock trade?
Can-Fite Biopharma Ltd (CANF) is listed on AMEX.What sector and industry is CANF in?
Can-Fite Biopharma Ltd operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CANF?
Can-Fite Biopharma Ltd has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $700.00 price target on 2026-05-13. Recent price targets range from $500.00 to $700.00.What companies are similar to CANF?
Notable peers in the same industry include RCUS (Arcus Biosciences Inc.), ITOS (iTeos Therapeutics Inc.), CRVS (Corvus Pharmaceuticals Inc.). Compare CANF side-by-side with any of them on Quantisnow.How can I track CANF on Quantisnow?
Quantisnow aggregates Can-Fite Biopharma Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CANF to receive live email and push alerts on every new disclosure.